HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestlé To Enter Europe's CBD Market With UK Launch

Executive Summary

Nestlé Health Science is expanding its CBD offering outside the US with the UK launch of a dietary supplement formulated by cannabis development firm Geocann.

You may also be interested in...



Last Minute UK CBD Rule Change Means Many More Products Can Remain On Market

CBD products linked to a submitted, rather than validated, novel food application can now remain on the UK market after 31 March, according to new guidance from regulator the Food Standards Agency. But will this merely cause more confusion for final product manufacturers, retailers and consumers? CBD expert and Canna Consultants co-founder Stephen Oliver thinks so. 

Thinking About Entering The EU CBD Market? Some Food For Thought

Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal. 

UK CBD Pathway Clear As EU Decides

The European Commission thinks that CBD might be a narcotic, after all. What should companies be doing while it decides? In this exclusive interview, regulatory expert Greer Deal – director at Global Regulatory Services – suggests that companies that haven’t already done so should consider filing Novel Food (NF) applications with both the European Commission and the UK Food Standards Agency.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel